I like to make regular, smaller investments in my portfolio to build up positions in ASX dividend shares that I’m bullish about. MFF Capital Investments Ltd (ASX: MFF) was the latest investment I made, with a $1,100 purchase.

I invested last week, when the price was a bit lower. But, when I talk about the dividend yield below, I’ll look at the yield at the time of writing.

I’m buying ASX dividend shares like MFF because of the investment exposure they provide as well as the compelling dividend payouts. One day, I’d love for my dividend income to be able to cover the core spending essentials in my life.

With that goal in mind, MFF looks like a leading contender for that purpose.

Strong dividend income

Let’s start with the passive income payments.

Over the past five years, the investment business has grown its six-monthly dividends at a compound annual growth rate (CAGR) of 26%.

It intends to grow its FY27 first-half dividend by another 20% to 12 cents per share and I expect the FY27 final dividend will be increased by 18% to 13 cents per share.

If the ASX dividend share does deliver on those expectations, the annual dividend per share would be 25 cents. That’s a FY27 grossed-up dividend yield of 6.6%, including franking credits.

That’s just the starting dividend yield – if it continues growing the payouts, then the dividend yield could quickly grow to more than 7%, then 8% and so on over the coming years.

Impressive investment process

A big factor in funding such a pleasing dividend history has been its investment performance.

Over the five years to 30 June 2026, its post-tax net tangible assets (NTA) has grown at an average of 14%.

With its portfolio, its goal is to build lasting wealth for shareholders through ownership of a portfolio of advantaged businesses.

Its investment mandate is unconstrained – it’s not limited to certain sectors, geographic markets or size of business. This flexibility allows the MFF to “adapt to changing investment market conditions and pursue opportunities that it identifies as offering attractive risk-adjusted investment returns”.

Currently, some of its biggest holdings include Mastercard, Alphabet, Visa, Bank of America, Amazon and Microsoft.

Capital growth

With those impressive investment returns, the business has only paid out part of its profits as dividends. The retained amounts can compound for investors, which is a key tailwind for the MFF share price.

Over the past five years, MFF shares have risen by 84%. I think it’ll continue rising in the long-term, though I’m not expecting the next five years to be as strong as the last five years, particularly with how it needs to fund its rising dividends.

But, as an ASX dividend share, it ticks the boxes of what I’m looking for.

The post Why I just invested $1,100 in this ASX dividend share appeared first on The Motley Fool Australia.

More reading

• How much do I need to retire on $75,000 a year at 45?
• How much is needed in superannuation to target a $70,000 annual passive income?
• Post-earnings: I’d buy these ASX dividend stocks for income today
• How much is needed in superannuation to target a $60,000 annual passive income?
• How much is needed in superannuation to target a $2,500 monthly passive income?

Motley Fool contributor Tristan Harrison has positions in Mff Capital Investments. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Mff Capital Investments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a very small gain. The benchmark index rose a fraction to 8,731.9 points.

Will the market be able to build on this on Tuesday? Here are five things to watch:

ASX 200 to rise

The Australian share market looks set for a good session on Tuesday following a strong night in the United States. According to the latest SPI futures, the ASX 200 is expected to open the day 28 points or 0.3% higher. On Wall Street, the Dow Jones rose 0.7%, the S&P 500 jumped 1.5%, and the Nasdaq stormed 2.25% higher.

Dividend payday

A group of ASX 200 shares will be rewarding their shareholders with their latest dividend payments on Tuesday. This includes Sigma Healthcare Ltd (ASX: SIG), Suncorp Group Ltd (ASX: SUN), and Coles Group Ltd (ASX: COL). The latter is paying shareholders a fully franked 37 cents per share dividend later today.

Oil prices tumble

ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a tough session on Tuesday after oil prices tumbled overnight. According to Bloomberg, the WTI crude oil price is down 4.9% to US$95.37 a barrel and the Brent crude oil price is down 3.6% to US$100.10 a barrel. This was driven by optimism that the US and Iran could start peace talks.

Gold price falls

ASX 200 gold shares Genesis Minerals Ltd (ASX: GMD) and Capricorn Metals Ltd (ASX: CMM) could have a soft session after the gold price dropped overnight. According to CNBC, the gold futures price is down 1% to US$4,381.3 an ounce. The precious metal has come under pressure due to increasing US rate hike bets.

Buy Telix shares

Telix Pharmaceuticals Ltd (ASX: TLX) shares could be in the buy zone according to Bell Potter. In response to its merger news, the broker has retained its buy rating and $19.00 price target on Telix’s shares. It said: “We are yet to include the earnings impact from the transaction in our forecast, nevertheless, it represents a once in a lifetime opportunity to acquire a dominant share in the supply of Lu-177 that is very difficult to replicate. While earnings may take a year or two to realise, the underlying value is obvious. Maintain Buy rating.”

The post 5 things to watch on the ASX 200 on Tuesday appeared first on The Motley Fool Australia.

More reading

• Should I buy Coles shares for passive income?
• Telix shares just crashed 12% on merger news. Time to buy the dip?
• Here are the top 10 ASX 200 shares today
• ASX 200 claws back its early losses. What’s moving the market?
• Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The CSL Ltd (ASX: CSL) share price has been one of the ASX’s best performers since early June 2026, rising about 90%. We’re going to look at the potential returns CSL could deliver in the year ahead.

The ASX biotech share had a difficult FY26, but FY27 looks much more positive.

In FY26, total revenue declined 1% to $15.8 billion, underlying net profit (NPATA) declined 2% to $3.1 billion, operating cash flow fell 1% to $3.5 billion and its net profit worsened by 184% to a net loss of $2.6 billion.

To go from a business regularly generating double-digit growth to a business seeing its underlying financials fall wasn’t appealing to investors.

However, FY27 looks much more positive for the business. We’ll look at the guidance for the upcoming year ahead and then look at what analysts are projecting for the CSL share price.

FY27 guidance

In the 2027 financial year, CSL expects revenue to be in line with the prior year and underlying NPAT growth of approximately 5%.

The CSL Behring division expects mid-single-digit revenue growth, with Ig growth in the mid-to-high single-digits. CSL said Behring will continue to focus on core plasma collection efficiency and manufacturing productivity.

CSL Seqirus expects low single-digit revenue growth. Immunisation rates in the United States are expected to decline, but at a slower rate than recent seasons.

The company also said that Vifor expects revenue to decline by approximately 25%, driven by “generic competition in iron products, the conclusions of the TDAPA period for VELPHORO, and the revocation of the marketing authorisation for TAVNEOS.

The company’s interim CEO and managing director Gordon Naylor gave some positive commentary with the outlook:

CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs.

The company’s ongoing strong cash flow and balance sheet have enabled us to announce a further A$1.1 billion share buy-back program and maintain our dividend.

What could happen with the CSL share price?

The CSL share price has risen enormously, and analysts seem to think it has peaked for now.

According to CMC Invest, the business has received 11 ratings in the last three months. The average price target is $175.02, implying it could trade at the same price a year from now.

The most optimistic price target is $213, implying a 12% rise. However, the most negative price target is $133, suggesting a possible 24% decline.

If it is flat over the next 12 months, there could be better ASX shares to buy today. 

The post How much could the CSL share price rise in the next year? appeared first on The Motley Fool Australia.

More reading

• CSL shares are back near $180. Here’s the level I’m watching
• Why brokers think CSL shares could be on track for $200
• Buy, hold, sell: Coles, NAB, CSL shares
• ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike
• How much passive income could I make by investing $500 a month in ASX shares?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.